cediranib + olaparib + durvalumab + capivasertib

**Cediranib + olaparib + durvalumab + capivasertib** is an investigational combination therapy composed of four agents:\n- **Cediranib** is an oral small molecule inhibitor targeting vascular endothelial growth factor (VEGF) receptors, inhibiting angiogenesis.\n- **Olaparib** is a poly (ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair in tumor cells, commonly used in BRCA-mutant cancers.\n- **Durvalumab** is a monoclonal antibody checkpoint inhibitor targeting PD-L1, enhancing anti-tumor immune responses.\n- **Capivasertib** is a small molecule inhibitor of AKT serine/threonine kinase, involved in the PI3K/AKT pathway, blocking oncogenic signaling.\nThis combination leverages anti-angiogenic, DNA-damage, immunotherapy, and targeted pathway inhibition modalities. Its primary development is in **advanced or metastatic solid tumors** such as endometrial cancer and metastatic triple negative breast cancer, in ongoing clinical trials[5][7][1][3].